

Highly Productive Pipeline Across Modalities



IMMUNOLOGY Respiratory and Dermatology

Target	Molecule	Modality	Development Lead	Preclinical	IND	Phase 1	Phase 2	Phase 3
TSLP	BSI-045B	Monoclonal Ab	CTTQ - SA&CRS (China)	[Progress bar from Preclinical to Phase 3]				
TSLP	BSI-045B	Monoclonal Ab	Aclaris - AD (Ex-China)	[Progress bar from Preclinical to Phase 2]				
IL4R	BSI-045A	Monoclonal Ab	CTTQ (China)	[Progress bar from Preclinical to Phase 3]				
TSLP x IL4R	BSI-502	Bi-specific Ab	Aclaris (Ex-China)	[Progress bar from Preclinical to Phase 1]				
CD40 antagonist	BSI-086	Monoclonal Ab	Biosion	[Progress bar from Preclinical to Phase 1]				
TSLPR	BSI-106	Monoclonal Ab	Biosion	[Progress bar from Preclinical to Phase 1]				
IL7R / TSLP	BSI-107	Monoclonal Ab	Biosion	[Progress bar from Preclinical to Phase 1]				

ONCOLOGY Solid Tumors

CD40 agonist	BSI-038	Monoclonal Ab	CTTQ (China)	[Progress bar from Preclinical to Phase 3]				
SIGLEC-15	BSI-060T	Monoclonal Ab	Pyxis (Ex-China)	[Progress bar from Preclinical to Phase 2]				
PD-1 x ILT4	BSI-585	Bi-specific Ab	Celldex (Ex-China)	[Progress bar from Preclinical to Phase 2]				
TROP2 ADC	BSI-992	ADC	OBI (Ex-China)	[Progress bar from Preclinical to Phase 2]				
SIRPα mAb	BSI-082	Monoclonal Ab	Biosion	[Progress bar from Preclinical to Phase 1]				
BTN3A1	BSI-093	Monoclonal Ab	Biosion	[Progress bar from Preclinical to Phase 1]				
HER2-5g9	BSI-001	Monoclonal Ab	Anke (China)	[Progress bar from Preclinical to Phase 1]				
CD40 x SIRPα	BSI-500	Bi-specific Ab	CTTQ (China)	[Progress bar from Preclinical to Phase 1]				